Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07820891) titled 'A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395' on Sept. 10.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: BeOne Medicines
Condition:
Healthy Adult Participants
Intervention:
Drug: BGB-43395
Drug: Midazolam
Drug: Celecoxib
Drug: Dabigatran etexilate
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: September 24, 2026
Target Sample Size: 24
To know more, visit https://clinicaltrials.gov/study/NCT07820891
...